Progyny (PGNY) Competitors

Progyny (NASDAQ:PGNY) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment, community ranking and analyst recommendations.

Does the media favor PGNY or HIMS?

In the previous week, Hims & Hers Health had 6 more articles in the media than Progyny. MarketBeat recorded 24 mentions for Hims & Hers Health and 18 mentions for Progyny. Progyny's average media sentiment score of 0.66 beat Hims & Hers Health's score of 0.54 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	6 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	13 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, PGNY or HIMS?

Progyny has higher revenue and earnings than Hims & Hers Health. Progyny is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.09B	1.64	$62.04M	$0.58	36.21
Hims & Hers Health	$872M	6.97	-$23.55M	$0.44	63.19

Do institutionals & insiders have more ownership in PGNY or HIMS?

94.9% of Progyny shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 12.3% of Progyny shares are held by insiders. Comparatively, 17.7% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor PGNY or HIMS?

Progyny received 59 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 71.43% of users gave Progyny an outperform vote while only 39.05% of users gave Hims & Hers Health an outperform vote.

Company	Underperform	Outperform
Progyny	Outperform Votes 100 71.43%	Underperform Votes 40 28.57%
Hims & Hers Health	Outperform Votes 41 39.05%	Underperform Votes 64 60.95%

Do analysts rate PGNY or HIMS?

Progyny currently has a consensus target price of $25.00, indicating a potential upside of 19.05%. Hims & Hers Health has a consensus target price of $25.13, indicating a potential downside of 9.60%. Given Progyny's higher probable upside, analysts plainly believe Progyny is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.31
Hims & Hers Health	2 Sell rating(s)	7 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.35

Which has more volatility & risk, PGNY or HIMS?

Progyny has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

Is PGNY or HIMS more profitable?

Hims & Hers Health has a net margin of 8.19% compared to Progyny's net margin of 5.03%. Progyny's return on equity of 11.36% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.03%	11.36%	7.87%
Hims & Hers Health	8.19%	10.97%	8.29%

Summary

Progyny beats Hims & Hers Health on 9 of the 17 factors compared between the two stocks.